You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,283,238


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,283,238
Title:Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Inventor(s): Bhamidipati; Somasekhar (Foster City, CA), Singh; Rajinder (Belmont, CA), Sun; Thomas (Palo Alto, CA), Masuda; Esteban (Menlo Park, CA)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:14/534,784
Patent Claims: 1. A method of treating an autoimmune disease in a mammal afflicted with the disease, the method comprising administering to the mammal an effective amount of an oral dosage formulation comprising a hydrate of the prodrug salt: ##STR00074## and a pharmaceutically-acceptable carrier, excipient, and/or diluent; wherein: M is Na; the prodrug salt hydrate present in the oral dosage formulation comprises crystalline prodrug salt hydrate; and the powder X-ray diffraction data of the crystalline prodrug salt hydrate comprises a characteristic peak at a two theta value of 9.9.+-.0.1.degree. in response to radiation of wavelength 1.54059 .ANG., wherein the autoimmune disease is associated with nonanaphylactic hypersensitivity reactions (Type II, Type III and/or Type IV hypersensitivity reactions) or mediated, at least in part, by activation of the Fc.gamma.R signaling cascade in monocyte cells.

2. The method according to claim 1, wherein the autoimmune disease is selected from the group consisting of Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy.

3. The method according to claim 1, wherein the autoimmune disease is selected from the group consisting of systemic lupus erythematosis, rheumatoid arthritis, Sjogren's syndrome, Reiter's syndrome, polymyositis-dermatomyositis, systemic sclerosis, polyarteritis nodosa, multiple sclerosis and bullous pemphigoid.

4. The method according to claim 1, wherein the autoimmune disease is selected from the group consisting of autoimmune alopecia, Type I or juvenile onset diabetes, and thyroiditis.

5. The method according to claim 1, wherein the autoimmune disease is rheumatoid arthritis or systemic lupus erythematosis.

6. The method according to claim 5, wherein the mammal is a human.

7. The method according to claim 6, wherein the formulation comprises from about 50 mg to about 400 mg of the crystalline prodrug salt hydrate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.